RiverVest Venture Partners’ Post

We are thrilled to announce the successful closing of our oversubscribed $97 million Series B financing. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from RiverVest Venture Partners, Novartis Venture Fund, funds managed by abrdn, Pictet Group, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital.    We thank our investors, team, and community partners who are joining Atalanta Therapeutics’ mission to advance RNAi medicines for serious neurological diseases. https://bit.ly/40Q603V #EQTLifeScience #SanofiVentures #FPrime #abrdn #RiverVest #GHRFoundation #NovartisVentureFund #Pictet #MiraeAsset #SeriesBFinancing #AtalantaTX 

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

AusperBio, a San Mateo, Calif.-based hepatitis B treatment developer, raised $73 million in Series B funding. HanKang Capital led the round and was joined by Sherpa Capital, CDH Investments, existing investors Qiming Venture Partners, InnoPinnacle Fund, YuanBio Venture Capital, and others. https://lnkd.in/dcmXjEpA #funding #hepatitisB #treatment #biopharma

We are delighted to start the year by announcing the closing of an oversubscribed CHF 50 million Series C extension, bringing the total Series C to CHF 180 million, to accelerate and further advance our pipeline of best-in-class and first-in-class multi-specific antibodies in inflammation and oncology. The financing was co-led by Cormorant Asset Management, Forbion, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, and BlackRock. We are looking forward to connecting with industry leaders next week during the 43rd Annual J.P. Morgan Healthcare Conference https://lnkd.in/eZBPTdbM in San Francisco.

𝐈𝐃𝐑𝐱'𝐬 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐨𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 IDRx has announced the successful completion of an oversubscribed $120M Series B financing, led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing. The funds will support the ongoing Phase 1/1b StrateGIST 1 study of IDRx's lead candidate, IDRX-42. Key highlights: • Fast Track designation granted by the U.S. FDA for IDRX-42. • Promising preliminary Phase 1 data, showing a 43% ORR in second-line GIST patients. • Strong backing from top-tier investors, including RA Capital, Andreessen Horowitz, and Merck KGaA. This milestone brings IDRx closer to its goal of transforming GIST treatment with precision therapies designed to address treatment resistance and adverse events. The company expresses its gratitude to the dedicated team, partners, and investors who continue to support its mission to elevate the standard of care for GIST patients. #Biotech #PrecisionMedicine #Oncology #GIST #ClinicalTrials 

Goldman Sachs Turns Bullish on MoonLake Immunotherapeutics: Strategic Insight for Investors In a significant move that has caught the attention of the investment community, Goldman Sachs has upgraded MoonLake Immunotherapeutics (NASDAQ: MLTX) from a "Neutral" to a "Buy" rating. This change comes with a revised price target of $82, up from $62, indicating a potential upside of nearly 80% from the current trading levels. Goldman Sachs' meticulous research and confidence in MoonLake's strategic direction highlight the promising developments in the company's clinical pipeline. With three new clinical trials underway, MoonLake is positioned for substantial growth in the biotech sector. For actionable insights and a deeper understanding of this potential investment opportunity, read the full article here: https://lnkd.in/eQ3nRUDx #Biotech #InvestmentInsights

#LSBCmember NEWS: NanoVation Therapeutics™ Announces Expansion of Board of Directors & Completion of Funding Round led by Convergent Ventures Read more here: https://lnkd.in/g6i5PS-U

❗𝗪𝗔𝗥𝗡𝗜𝗡𝗚: 2 Discounted Passes Left for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   Time is running out to be part of the 𝗺𝗼𝘀𝘁 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. Don't risk falling behind as top experts 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 and share their 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.   𝗚𝗿𝗮𝗯 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 - https://ter.li/ntamqp   Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field.   ⏳ 𝗦𝗮𝘃𝗲 $𝟯𝟬𝟬 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 - https://ter.li/ook4wg   Don't let this opportunity slip away!   #MacrophageDirectedTherapiesSummit

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

💰💲 Looks like VC's are keeping those chequebooks open for another week, as have another 5 key fundraising deals to bring you this week. You'll be pleased to know it's another high value week with over $600 million worth of investment with some new companies entering the mix, and some who are getting their second cash injection of 2024! 🦠Avenzo Therapeutics - $386 million oversubscribed series A 🍃Enveda - $130 million series C 🧬atbtherapeutics - €54 million series A 🧫Valora Therapeutics, Inc. - $30 million seed funding 💉Zucara Therapeutics Inc. - $20 million series B #financialfridays #biotechinvestment #venturecapitalist #vcinvestment